Carbidopa and Levodopa NDC 51079-978

NDC codes

FDA NDC Directory

Product NDC (as listed)51079-978Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51079-0978Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51079-978-20	51079097820	100 BLISTER PACK in 1 CARTON (51079-978-20) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (51079-978-01)Marketed from Feb 1, 2002

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa and Levodopa
Generic name (nonproprietary): carbidopa and levodopa
Active ingredients: Carbidopa — 25 mg/1Levodopa — 100 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Mylan Institutional Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075091
Marketing start: Feb 1, 2002
Listing expires: Dec 31, 2026
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 51079-978_3a39bb13-44d1-2652-e063-6294a90ad211SPL ID 3a39bb13-44d1-2652-e063-6294a90ad211SPL set ID 16f9e4d1-6953-4d4f-b4cf-ad95a856ac25RxCUI 308988, 308989UNII MNX7R8C5VO, 46627O600J
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451079097820 followed by a unit qualifier and the quantity

Package 51079-0978-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 18, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075091

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075091
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa and Levodopa	Carbidopa hydrate 25 mg/1; Levodopa 100 mg/1	Tablet, Extended releaseOral	Safecor Health, LLC	48433-015
Carbidopa and Levodopa	Carbidopa hydrate 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Safecor Health, LLC	48433-016
Carbidopa and Levodopa	Carbidopa 25 mg/1; Levodopa 100 mg/1	Tablet, Extended releaseOral	Mylan Pharmaceuticals Inc.	0378-0088
Carbidopa and Levodopa	Carbidopa 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Mylan Pharmaceuticals Inc.	0378-0094
Carbidopa and Levodopa	Carbidopa 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Mylan Institutional Inc.	51079-923